Merck Extends Timeline On Acceleron Deal, Still Expects Q4 Close
Some Investors Have Voiced Concern About Buyout
Merck said it is giving the FTC more time to review the acquisition, but the shift also gives the company leeway to convince any reluctant Acceleron shareholders to trade their shares for cash.
You may also be interested in...
The US pharma giant is planning ahead for Keytruda’s swansong, and hopes that wave of new cardiovascular drugs can help maintain its growth into the next decade.
Totals for aggregate deals and in the M&A, alliance and divestment categories were similar among the 10 busiest deal makers from 2020 to 2021, but COVID-19 may have driven a more hectic deal-making pace overall in 2020.
The emergence and rapid spread of the Omicron variant has kept COVID-19 firmly in the headlines but the biopharma industry has had plenty on its plate on top of tackling the pandemic. Scrip has taken a look back at five of the biggest non-COVID-19 story themes of 2021 in no particular order.